Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Lyon, Alexander R.; Dent, Susan; Stanway, Susannah; Earl, Helena; Brezden‐Masley, Christine; Cohen‐Solal, Alain; Tocchetti, Carlo G.; Moslehi, Javid J.; Groarke, John D.; Bergler‐Klein, Jutta; Khoo, Vincent; Tan, Li Ling; Anker, Markus S.; Haehling, Stephan von; Maack, Christoph; Pudil, Radek; Barac, Ana; Thavendiranathan, Paaladinesh; Ky, Bonnie; Neilan, Tomas G.; Belenkov, Yu. N.; Rosen, Stuart D.; Iakobishvili, Zaza; Sverdlov, Aaron L.; Hajjar, Ludhmila Abrahão; Macedo, Ariane Vieira Scarlatelli; Manisty, Charlotte; Ciardiello, Fortunato; Farmakis, Dimitrios; Boer, Rudolf A. de; Skouri, Hadi; Suter, Thomas; Cardinale, Daniela; Witteles, Ronald; Fradley, Michael G.; Herrmann, Joerg; Cornell, Robert F.; Wechelaker, Ashutosh; Mauro, Michael J.; Milojković, Dragana; Lavallade, Hugues de; Ruschitzka, Frank; Coats, Andrew J.S.; Seferović, Petar; Chioncel, Ovidiu; Thum, Thomas; Bauersachs, Johann; Andrés, María Sol; Wright, David J.; López‐Fernández, Teresa; Plummer, Chris; Lenihan, Daniel J.

doi:10.1002/ejhf.1920

articleEuropean Journal of Heart FailureMay 28, 2020BRONZE OA

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

ARAlexander R. Lyon SDSusan Dent SSSusannah Stanway HEHelena Earl CBChristine Brezden‐Masley

Royal Brompton Hospital · Imperial College London · +91 more institutions

PubMed

Indexed incrossrefdatacitepubmed

Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial…

Citation impact

753

total citations

FWCI: 59.25
Percentile: 100%
References: 93

Citations per year

Authors

52

Topics & keywords

Topics

Keywords

Medicine
Internal medicine
Cancer
Cardiotoxicity
Oncology
Trastuzumab
Risk assessment
Heart failure

No related works found for this paper.